Copyright © Inderes 2011 - present. All rights reserved.

Orion

47,09 EUR +1,51%
13.811 investorer følger denne virksomhed

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

P/E (adj.) (24e)
22,11
EV/EBIT (adj.) (24e)
17,41
P/B (24e)
6,88
Udbytteafkast, % (24e)
3,5 %
Kursmål
45.00 EUR
Anbefaling
Reducer
Opdateret
12.9.2024
NASDAQ Helsinki
ORNBV
Daglig lav / høj pris
46,2 / 47,13 EUR
Markedsværdi
6,65 mia. EUR
Aktieomsætning
4,59 mio. EUR
Volumen
98 t
Business risk
Valuation risk
Current
Previous

Analytiker

Antti Siltanen
Antti Siltanen
Analytiker

Seneste videoer

Orion Oyj, Q2'24
08.08.2024
Orion Oyj, Q1'24
25.04.2024
Orion Q4'23 – Tuesday, Feb. 13 at 1:30 pm EET
13.02.2024

Finanskalender

Halvårligt udbytte
15.10.2024
Delårsrapport
29.10.2024
Generalforsamling
03.04.2025
Delårsrapport
23.04.2025
Delårsrapport
18.07.2025

Resultatopgørelse

20202021202220232024e2025e2026e2027e
Omsætning1.078,11.041,11.340,61.189,61.476,61.504,51.648,21.783,5
vækst-%2,6 %-3,4 %28,8 %-11,3 %24,1 %1,9 %9,5 %8,2 %
EBITDA336,5289,0486,6326,4430,4359,9432,4509,1
EBIT (adj.)280,1243,3439,6274,9379,9315,9379,1454,8
EBIT280,1243,3439,6274,9379,9315,9379,1454,8
Overskud før skat278,3242,3440,3271,9377,5313,6377,0453,5
Netto indkomst219,9193,8349,5216,8299,2247,8297,8358,2
EPS (adj.)1,571,382,491,542,131,762,122,55
vækst-%9,9 %-11,9 %80,3 %-38,0 %38,0 %-17,2 %20,2 %20,3 %
Udbytte1,501,501,601,621,651,701,751,80
Udbytte ratio95,8 %108,7 %64,3 %105,0 %77,5 %96,4 %82,5 %70,6 %

Lønsomhed og afkast på kapital

20202021202220232024e2025e2026e2027e
EBITDA-%31,2 %27,8 %36,3 %27,4 %29,1 %23,9 %26,2 %28,5 %
EBIT-% (adj.)26,0 %23,4 %32,8 %23,1 %25,7 %21,0 %23,0 %25,5 %
EBIT-%26,0 %23,4 %32,8 %23,1 %25,7 %21,0 %23,0 %25,5 %
ROE29,1 %26,8 %43,1 %24,1 %32,3 %25,6 %29,6 %32,8 %
ROI34,4 %29,5 %45,6 %24,9 %34,8 %28,9 %33,8 %38,8 %

Værdiansættelse

20202021202220232024e2025e2026e2027e
Aktiekurs (EUR)40,9536,6649,7037,5047,0947,0947,0947,09
Aktier140,5140,5140,5140,5140,5140,5140,5140,5
Markedsværdi5.752,05.149,46.981,05.267,46.614,46.614,46.614,46.614,4
Enterprise value5.566,24.960,06.862,45.360,76.614,46.599,76.576,66.503,1
EV/S5,24,85,14,54,54,44,03,6
EV/EBITDA16,517,214,116,415,418,315,212,8
EV/EBIT (adj.)19,920,415,619,517,420,917,314,3
EV/EBIT19,920,415,619,517,420,917,314,3
P/E (adj.)26,226,620,024,322,126,722,218,5
P/E26,226,620,024,322,126,722,218,5
P/B7,97,27,75,96,96,86,45,8
P/S5,34,95,24,44,54,44,03,7
Udbytteprocent3,7 %4,1 %3,2 %4,3 %3,5 %3,6 %3,7 %3,8 %
Equity ratio65,6 %66,0 %60,4 %61,9 %65,6 %66,4 %67,7 %72,1 %
Gearing ratio-25,4 %-26,5 %-13,1 %10,5 %-0,0 %-1,5 %-3,6 %-9,7 %

Kvartalsdata

Q3/23Q4/232023Q1/24Q2/24Q3/24eQ4/24e2024eQ1/25e
Omsætning301,0321,11.189,6308,5328,2448,6391,41.476,6
EBITDA92,7106,6326,467,080,3149,3133,8430,411,0
EBIT79,992,9274,956,065,8136,8121,3379,9
Overskud før skat78,592,5271,954,965,1136,5121,0377,5
Netto indkomst61,475,2216,843,752,0107,895,6299,2
Login in to make your own estimates and see other investors estimates.
ViserAlle indholdstyper

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account